Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...
The underlying pathophysiological mechanisms are still not clear and a ‘GABA hypothesis' has been proposed. Most patients respond well to benzodiazepines or ECT and prompt treatment in the early ...